Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) has a dated narrative snapshot, but its priced-in model claim is temporarily suppressed because the model-solve record is unavailable or has changed.
282 institutional managers reported holding RARE in 13F filings for the quarter ended 2026-03-31. 52 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 14.3M shares were sold short as of the 2026-06-15 count, about 14% of shares outstanding (8.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
RARE's share count grew 48.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at RARE over the trailing three years. Absence is a fact about the company, not a signal. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
RARE's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | -11.1% | -6.5% |
| 2023-11-04 | +7.7% | +22.6% |
| 2024-02-22 | +7.1% | -10.3% |
| 2024-05-04 | -1.3% | -4.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
RARE's latest 8-K filings: 2026-08-04 (items 2.02, 9.01); 2026-05-18 (items 5.02, 5.07, 9.01); 2026-05-05 (items 2.02, 9.01); 2026-04-02 (items 8.01); 2026-03-30 (items 8.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: August 8, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.